1 (0 min vs 20 min) and in between hospitals (
median time 0.0 min in Mumbai to 1.5 h in Kolkatta) and
2 erval: 11 (4%) delays for 24-hour intervals (
median time,
18.52 hr); 31 (26%) for 12-hour intervals (
3 nts (75 PI-mono) had neurocognitive testing (
median time after randomization 3.8 years), of whom 78 w
4 es acquired both after endovascular therapy (
median time after symptom onset, 12 hours) and at day 5
5 ipients with characteristic ABMR morphology (
median time after transplant, 5.0 years; pretransplant D
6 The
median time at which PHD developed was 41 mo after the f
7 The
median time-
averaged milk-to-plasma concentration ratio
8 The
median time awake and number of prolonged disruptions we
9 Median time between baseline and follow-up cardiac MR im
10 The
median time between delivery and cord clamping was 5 sec
11 The
median time between hospital discharge and positive cult
12 Median time between infection and cART initiation was 41
13 The
median time between initial injury and referral was 3.72
14 The
median time between invitations (2.37 years) was used as
15 The estimated
median time between medication intake and coma was 5 min
16 Overall, the
median time between removal and reimplantation was 10 da
17 The
median time between sample collection and diagnosis was
18 The
median time between the 2 scans was 2.2 mo (range, 0.2-4
19 Results: The
median time delay between research PET and surgery was 2
20 The
median time delay between research PET and surgery was 2
21 Median time difference between goal-directed echocardiog
22 The
median time elapsed between the end of chemotherapy and
23 From the
median time for preventive therapy initiation (50 days),
24 tocol was associated with a reduction in the
median time for PSC arrival to CSC groin puncture (from
25 The
median times for obtaining PZA results from the time whe
26 patients (105 receiving IV metoprolol), the
median time from 15 mg metoprolol bolus to reperfusion w
27 hort- and long-interval groups, split by the
median time from 15 mg metoprolol bolus to reperfusion.
28 mance time relative to baseline (decrease in
median time from 43.7 s [IQR 26.1-68.0] to 29.7 s [21.4-
29 The
median time from admission to infection was 19 days (int
30 The
median time from an offer of immediate ART to starting A
31 The
median time from aortic valve replacement to CT for the
32 The
median time from approval to first postmarket safety eve
33 After propensity score matching, the
median time from arrival in the cardiac catheterization
34 The
median time from ASCT to second-line therapy was 24.3 mo
35 death for each type of synucleinopathy, the
median time from diagnosis to death, and the causes of d
36 Median time from diagnosis to enrollment was 5 weeks, an
37 ed for assessment of post-diagnostic intake (
median time from diagnosis to the dietary assessment, 2.
38 70 minutes (range, 30-2572 minutes), and the
median time from diagnosis to treatment of sICH was 112
39 le), median age was 29 years (IQR 20-36) and
median time from discharge from an EVD treatment facilit
40 Pri by 1 year postmyocardial infarction; the
median time from discharge to cessation was 200.5 days (
41 The
median time from Ebola treatment unit discharge to speci
42 The
median time from end of the procedure to catheter utiliz
43 Median time from first medical contact to antibiotic adm
44 Results The
median time from groin puncture to first intracranial fl
45 The
median time from hospital discharge to completed suicide
46 median incubation period was 1 day, and the
median time from illness onset to hospital admission was
47 The
median time from initial cataract diagnosis to date of f
48 The
median time from initiation of rtPA therapy to sICH diag
49 Median time from insertion to detection and the percenta
50 Median time from onset of AID to diagnosis of myeloid ne
51 The
median time from orchiectomy to relapse was 19 months (9
52 an age, 44 years [SD, 15]; women, 274 [57%];
median time from orthopedic implant placement, 11 months
53 The
median time from palliative care consultation to death w
54 Median time from presentation to first study drug was le
55 n < 10 g/dL in 17%, liver metastases in 30%,
median time from prior chemotherapy of 3.6 months, and E
56 The
median time from randomization to coronary angiography w
57 The
median time from recurrence to death or heart transplant
58 Median time from relapse to retreatment was 22 weeks.
59 trials were requested at least once, and the
median time from repository availability to first reques
60 Median time from RT to SNHL onset was 3.6 years (range,
61 Median time from school was 25 years (range 9-55 years).
62 Median time from starting ibrutinib to occurrence of PCP
63 Median time from stroke onset to treatment was 6.9 h (IQ
64 Median time from study completion to data availability w
65 In the intervention group, the
median time from study CT of the head to first reperfusi
66 Median time from symptom onset to arterial puncture was
67 years, median NIH Stroke Scale [NIHSS] = 16,
median time from symptom onset to endovascular therapy =
68 Median time from TAVR to infective endocarditis was 5.3
69 f 7 days after the onset of illness, and the
median time from the onset of symptoms to clearance of v
70 The
median time from the start of mold-active antifungal the
71 Median time from transplantation and cGVHD onset was 616
72 The
median time from week 24 to the first intravitreal aflib
73 23%) had at least 1 aPL present at baseline (
median time interval from baseline to death, 4.6 years),
74 The
median time needed to process and analyze a sample with
75 PSC door in to door out that reduced from a
median time of 104 minutes (95% CI, 82-112 minutes) to a
76 at baseline and no clinical relapse) after a
median time of 12 weeks of therapy; all had a sustained
77 At a
median time of 16.8 years after disease onset, 10.7% (95
78 7 patients met the primary outcome within a
median time of 2 weeks following the first gevokizumab i
79 ent HCC developed in 356 (54%) patients at a
median time of 22 months from primary resection.
80 te in 61.5% of patients and occurred after a
median time of 3 hours after extracorporeal life support
81 ight of whom developed a malignancy within a
median time of 3 months from diagnosis of MN.
82 Cryptosporidiosis occurred at a
median time of 3.4 (0-19.8) years posttransplant.
83 535 of 8,577 hospital survivors (6.2%) at a
median time of 300 days (interquartile range: 130 to 509
84 multiple organ failure, and occurred after a
median time of 4 days.
85 nd 55 patients achieved a second UMRD with a
median time of 4 months (range, 1 to 16 months).
86 Relapses occurred after a
median time of 4 months (range: 1-38).
87 mor in the contralateral kidney (n = 1) at a
median time of 4.3 months for those who relapsed (range
88 of 104 minutes (95% CI, 82-112 minutes) to a
median time of 64 minutes (95% CI, 51-71.0 minutes) (P <
89 e was 3.6 cm (1.6-5.5 cm), and occurred at a
median time of 65.5 months (2-183 months) posttransplant
90 Aboveground biomass stocks took a
median time of 66 years to recover to 90% of old-growth
91 developed RD after cataract surgery, with a
median time of 70 months.
92 The
median time of day for extubation with an extubation rea
93 Median time of death for patients with FMF was 61 months
94 posure to short-course antiretrovirals), the
median time of follow-up from VS was 322 days.
95 Median time of follow-up observation was 66.6 weeks (ran
96 Median time of follow-up was 2 years (range 2 to 3 years
97 in 106 patients with primary HIV infection (
median time of measurement, 91 days after infection), co
98 %) reported predominantly illusions with the
median time of onset at 19.5 months follow-up.
99 We included 1422 participants (
median time of pain disorder 10 years [IQR 5-20]; median
100 In days,
median time of result return for POCT was 1 day, signifi
101 The
median time of reverse-transcription polymerase chain re
102 tients meeting our eligibility criteria, the
median time on ART to 31 December 2014 was 33.6 months (
103 Mean age was 41 years, 70% were females, and
median time on ART was 3.4 years.
104 Median time on dialysis before transplantation was 18.5
105 The
median time on ibrutinib was 4.7 months (range 0.7-43.6)
106 In the 48 patients included in analysis,
median time on surveillance from registration on study u
107 Median time on therapy was 12.1 months and 23.1 months f
108 The
median time on veno-venous extracorporeal membrane oxyge
109 b as compared with placebo (39% reduction in
median time,
P=0.005).
110 Serum samples were collected over a
median time period of 10 years and analyzed for antibodi
111 Median time (
Q1, Q3) from meeting full eligibility crite
112 The
median time required for near-patient testing from sampl
113 sults Median age at evaluation was 37 years;
median time since chemotherapy was 4.3 years.
114 In part 2 (32 patients),
median time since diagnosis was 3.2 years, with a median
115 ients enrolled, median age was 66 years, and
median time since diagnosis was 5.3 years.
116 In part 2, the
median time since diagnosis was 5.7 years.
117 between February 13, 1999 and June 15, 2005 (
median time since HCT: 7.9 years); HCT survivors were fo
118 Median time since last regimen was 1.5 months.
119 ian age = 30.5 years, 87.2% moderate-severe,
median time since TBI = 16.3 months, n = 4 with GHD) wer
120 s (median age, 70 years) were included whose
median time since their last treatment was 3.9 months (r
121 Median time taken and path length were significantly sho
122 isingly, Giardia cytokinesis occurred with a
median time that is approximately 60 times faster than m
123 ng/mL and 34 800 ng/mL and was reached in a
median time (
tmax) between 1.5 h and 4 h, with a mean el
124 The
median time to achieve 20/200 visual acuity was 1 month
125 mg of omalizumab with 24 weeks of treatment,
median time to achieve a UAS7 </= 6 was 6 weeks (ASTERIA
126 /= 6 was 6 weeks (ASTERIA I and GLACIAL) and
median time to achieve a UAS7 = 0 was 12 or 13 weeks (AS
127 Median time to acute respiratory distress syndrome devel
128 The
median time to admission was 2 h (IQR 1-3) with a bedsid
129 Among ICM patients with AF detected, the
median time to AF detection was 8.4 months, 81.0% of fir
130 The
median time to antibiotic administration was 2.1 hours (
131 The
median time to antimicrobial was 3.77 hours (interquarti
132 Median time to ART was 1 day (IQR 1-1) in the urgent gro
133 Median time to autopleurodesis was shorter in the aggres
134 The
median time to best HR was 3 cycles, and median duration
135 The
median time to biochemical, symptomatic, or radiographic
136 Median time to clearance was 2 days, with a range of 1-7
137 Median time to CLIA-validated results was 116 days with
138 Median time to clinical remission was 41.9 months in pat
139 Compared with a
median time to clinical response of 5.14 days in the 600
140 the 600 mg intravenous zanamivir group, the
median time to clinical response was 5.87 days (differen
141 Median time to clinically meaningful deterioration was a
142 In both groups,
median time to collection of treatment was within 1 day
143 o HPE quicker than those without expression (
median time to complete remission, 4.0 months vs 5.0 mon
144 Median time to complete resolution of subretinal fluid o
145 The
median time to complete resolution was 8.0 hours (interq
146 The
median time to completion of the 3-hour bundle was 1.30
147 (interquartile range, 0.35 to 1.95), and the
median time to completion of the fluid bolus was 2.56 ho
148 to distant recurrence was 25 months, and the
median time to concurrent local and distant recurrences
149 133 hours, P < .001), a significantly longer
median time to CT (+25 hours, 42 vs 17 hours, respective
150 Median time to culture conversion was 85 days (range, 8-
151 added mortality and only small reductions in
median time to culture conversion, the optimal strategy
152 The
median time to cure was similar between the "prolonged-c
153 Of those who died,
median time to death 8.9 hours (range, 4 min to 7 d).
154 harged patients had failed treatment, with a
median time to death after discharge of 9.9 months (IQR
155 The
median time to death was 4.2 years (IQR, 2.2-7.1 years).
156 Median time to death was 9.7 years in the exposed group
157 Median time to definitive deterioration in FACT-G total
158 The
median time to detect significant deterioration with MD
159 of asymptomatic first episodes and the long
median time to detection, these findings highlight the l
160 Median time to deterioration was significantly longer wi
161 Among eyes without DDAF at first visit, the
median time to develop a DDAF lesion was 4.9 years (95%
162 Among eyes without QDAF, the
median time to develop a QDAF lesion was 6.3 years (95%
163 The
median time to development of skin lesions was 3.5 month
164 The
median time to development of transaminitis was 28 days,
165 The
median time to diagnosis of SSI was 25 days (interquarti
166 neuroimaging was non-diagnostic in AIS, then
median time to diagnosis was 44 h.
167 time to local recurrence was 43 months, the
median time to distant recurrence was 25 months, and the
168 Teledermatology reduced
median time to evaluation from 70.0 days (interquartile
169 Median time to evaluation; percentage of patients evalua
170 n the cohort, 2616 met the primary endpoint (
median time to event of 14.5 years) and 721 developed he
171 In total, 104 patients experienced MACE (
median time to event, 36 weeks).
172 The
median time to first chest compression decreased from 25
173 ation, all abnormal ophthalmic findings (and
median time to first diagnosis), visual acuities, and op
174 Median time to first follow-up RHC was 4.6 months (inter
175 The
median time to first Giardia positive surveillance stool
176 The
median time to first recurrence of angioedema was 57-63
177 The
median time to first reintervention was 9.8 years.
178 gnosis predicted subsequent relapse, and the
median time to first relapse was 30 months (maximum, 10
179 The
median time to first response was 1.0 month (range 0.9-5
180 Median time to fixation was 15 hours (IQR 7-24 hours) an
181 to 2 (0-3) assessed after at least 3 months (
median time to follow-up = 120 days).
182 ross dose levels who achieved CR or CRi, the
median time to full count recovery was 6.4 weeks for neu
183 Median time to genome analysis was 5 days (range 3-153)
184 On the other hand, the
median time to graft rejection was 28 +/- 5.2 days and 1
185 The
median time to growth cessation in the 26 PGN that stabi
186 Median time to GVHD onset was 28 days.
187 Median time to HCC recurrence was 13.8 months (1-75) aft
188 The
median time to HF and/or CM was 456 days in trastuzumab
189 Median time to HRQoL improvement was shorter in patients
190 nterquartile range [IQR], 15-32) points, and
median time to IA treatment was 288 (IQR, 216-380) minut
191 Median time to improved response was 12.2 weeks (IQR 7.2
192 Median time to infection was 35 days for initial and 23
193 Median time to initial CMV reactivation was 41 days (ran
194 The
median time to initiation of appropriate treatment was 7
195 The
median time to last unformed stool did not differ betwee
196 Donors were listed earlier (
median time to listing, 17 months vs 120 for nondonors;
197 nce interval [CI]: 4 months, 12 months); the
median time to local progression after IRE was 12 months
198 atment was 100 months (14-365 months), while
median time to local recurrence was 43 months (9-185 mon
199 The
median time to local recurrence was 43 months, the media
200 A Kaplan-Meier estimate of the
median time to melanoma among those patients who did dev
201 Nevertheless, ATM inhibition reduced
median time to moribund in Cdkn1a(p21(CIP/WAF1))-/- mice
202 9.25 Gy total body irradiation (TBI) reduced
median time to moribund in mice to 8 days.
203 on using AZD6738 prior to TBI did not reduce
median time to moribund.
204 otherapy was seen earlier with ctDNA, with a
median time to nadir of 37 d (IQR 28-54) compared with a
205 to nadir of 37 d (IQR 28-54) compared with a
median time to nadir of 84 d (IQR 42-116) for CA-125.
206 Median time to neutrophil and platelet recovery was 11 d
207 The percentage of patients and
median time to occurrence of complications were as follo
208 The
median time to onset of grade 2 or higher HFS was not re
209 Median time to onset of grade 3/4 treatment-related sele
210 Median time to onset of select AEs ranged from 5 weeks f
211 Median time to onset was 9.0 days, and median peak ammon
212 30.6 percentage points]; P < 0.001), and the
median time to overall response was shorter in the multi
213 was diagnosed in 2673 recipients (11.5%).The
median time to overall, skin, solid posttransplant malig
214 The
median time to PBT after baseline therapy was 60 and 75
215 anibizumab and an increase of 30 days in the
median time to PBT for the 6.0-mg dose.
216 The
median time to platelet engraftment was 27 days.
217 Median time to PPMS was 3.5 years (range, 1.6-5.4).
218 Median time to prednisone discontinuation was 35.8 month
219 Median time to progression and duration of response were
220 The
median time to progression and median progression-free s
221 a promising overall response rate of 36% and
median time to progression of 8.5 (6.0, 38.7) mo and ove
222 The
median time to progression was 57.3 months (95% CI 44.2-
223 The
median time to progression/discontinuation was 6.6 month
224 For eyes that progressed to RD surgery, the
median time to pseudophakic RD surgery was 44 days for e
225 Median time to PTLD diagnosis was 8.3 (range, 1.2-13.9)
226 The
median time to readmission or death was 4.3 months (IQR,
227 Median time to readmission was 30 days for all readmissi
228 The
median time to rebound was 4 weeks in the A5340 trial an
229 within 4 months of full-dose TKI resumption (
median time to recovery 77 days).
230 The
median time to recovery of kidney function was 15 days w
231 Median time to recovery to baseline ferritin levels in t
232 nd cytokeratin-expressing CTCs had decreased
median time to recurrence compared with patients without
233 Median time to recurrence decreased with increasing prev
234 Median time to recurrence was 14 months, and median foll
235 ll recurrence rate was 24% (n = 17), and the
median time to recurrence was 16 months (range: 4-132 mo
236 The
median time to recurrence was 18 months (range 4-156 mon
237 Median time to recurrence was shorter in liver-only recu
238 stent with HT, and 154 had untransformed FL (
median time to recurrence, 9.6 v 22.8 months, respective
239 Median time to recurrent AKI within 12 months was 64 (in
240 ent for the 3 seed classes (P < 0.0001): the
median time to regression was 0.6, 1.7, and 7.7 months f
241 Median time to reintubation did not significantly differ
242 Median time to reintubation was 15 hours (interquartile
243 post-release compared with VTC participants (
median time to relapse 31 days [IQR 26-32] vs 352 days [
244 The
median time to relapse following the first injection was
245 to extended-release naltrexone had a longer
median time to relapse than did those assigned to usual
246 For 5 patients who relapsed, the
median time to relapse was 12 weeks (range, 6-41 weeks).
247 Median time to replacement was 5.0 years (Q1-Q3, 4.4-5.6
248 ks, and with the exclusion of endocrine AEs,
median time to resolution from onset ranged from 1.9 (re
249 % CI, 31% to 59%; 14 of 31 patients), with a
median time to resolution of 41.5 weeks.
250 dian of 3 doses, and 4 hours after the dose;
median time to resolution was 24 hours.
251 Median time to response was 1 month.
252 The
median time to response was 1.1 months in the ixazomib g
253 ty, the overall response rate was 18.5%, the
median time to response was 17.9 weeks (range, 7.3 to 32
254 Median time to response was 3.3 months (IQR 2.2-4.8), an
255 Median time to response was 4 weeks (range, 4 to 36 week
256 Median time to response was approximately 1.8 months.
257 The
median time to revision for patients who had surgery you
258 After band removal, the
median time to revisional surgery was 1 year (95% confid
259 Median time to second-line DST was 53 days (range, 8-259
260 The
median time to stage 4 or higher CKD after surgery was 5
261 genome analysis was 5 days (range 3-153) and
median time to STATseq report was 23 days (5-912).
262 n, 58.2%) were included in the study, with a
median time to study drug administration of 3.5 hours af
263 The
median time to successful intubation was 3 minutes (rang
264 61 years; 49.7% male) with 2 colonoscopies (
median time to surveillance, 4.9 years).
265 urs (interquartile range, 0.65 to 2.35), the
median time to the administration of antibiotics was 0.9
266 mong the patients who could be assessed, the
median time to the cessation of bleeding was 2.5 hours.
267 The
median time to the end of angiography with CS was 104 mi
268 The
median time to the first crisis was significantly longer
269 re was also no significant difference in the
median time to the first laboratory-confirmed infection:
270 The
median time to the first outpatient follow-up visit afte
271 In group B, the
median time to the initiation of the intended procedure
272 (4.07 vs. 1.38 months, P=0.001), as was the
median time to the second crisis (10.32 vs. 5.09 months,
273 patients diagnosed with THV thrombosis, the
median time to THV thrombosis post-transcatheter aortic
274 The
median time to transformation was 35 months (range, 6-26
275 emonstrate how this information differs from
median time to transplant.
276 Median time to transplantation for such patients is doub
277 tment initiation (range 51%-73% by 6 mo) and
median time to treatment (range 15-36 d, n = 1,450), and
278 The
median time to treatment decision was shorter with EBUS-
279 The
median time to treatment decreased from 44 d (interquart
280 Median time to treatment failure was 16.7 months in pati
281 The
median time to treatment failure was 24 weeks in the ada
282 e survival was 7.1, 4.9, and 6.8 months; and
median time to treatment failure was 5.6, 4.3, and 6.7 m
283 days) to 0.5 days (IQR, 0.172-0.94 days) and
median time to treatment from 73.5 to 3.0 days compared
284 Median time to treatment termination was significantly s
285 Median time to tumor progression (tumor volume larger th
286 e group (HR, 1.057; 95% CI, 0.949 to 1.177),
median time to tumor progression was 7.5 months in both
287 t blocks viral replication, showing that the
median time to undetectable plasma viral load (VL) can b
288 Excluding those with resistant virus, the
median time to virus negativity was 5.5 days in pocapavi
289 ed after hospital discharge, with a 19.5-day
median time to VTE.
290 Median times to death of patients at high (0.94 years, n
291 Median times to decompensation of patients at high (1.76
292 Median times to GI bleeding were <90 days for apixaban a
293 Median times to last follow-up were 17.0 (interquartile
294 Median times to neutrophil and platelet engraftment were
295 achieved complete molecular responses, with
median times to response of 22.2 and 27.5 months, respec
296 Median times to transition for these cascade stages were
297 Median time until first progression or death for rotatin
298 In per-protocol analyses, the
median time-
weighted average glucose level was significa
299 The
median time-
weighted average LDL cholesterol level durin
300 E/S achieved a significantly lower
median time-
weighted average low-density lipoprotein cho